Your browser doesn't support javascript.
loading
Light-enhanced VEGF121/rGel: A tumor targeted modality with vascular and immune-mediated efficacy.
Weyergang, Anette; Fremstedal, Ane S; Skarpen, Ellen; Peng, Qian; Mohamedali, Khalid A; Eng, Marius S; Cheung, Lawrence H; Rosenblum, Michael G; Waltenberger, Johannes; Berg, Kristian.
Afiliação
  • Weyergang A; Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University hospital, Norway. Electronic address: anette.weyergang@rr-research.no.
  • Fremstedal AS; Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University hospital, Norway.
  • Skarpen E; Department of Molecular Cell Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University hospital, Norway.
  • Peng Q; Department of Pathology, Norwegian Radium Hospital, Oslo University hospital, Norway.
  • Mohamedali KA; Department of Experimental Therapeutics, Immunopharmacology and Targeted Therapy Laboratory, M.D. Anderson Cancer Center, Houston, TX, United States.
  • Eng MS; Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University hospital, Norway.
  • Cheung LH; Department of Experimental Therapeutics, Immunopharmacology and Targeted Therapy Laboratory, M.D. Anderson Cancer Center, Houston, TX, United States.
  • Rosenblum MG; Department of Experimental Therapeutics, Immunopharmacology and Targeted Therapy Laboratory, M.D. Anderson Cancer Center, Houston, TX, United States.
  • Waltenberger J; Department of Cardiovascular Medicine, University of Münster, Münster, Germany.
  • Berg K; Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University hospital, Norway.
J Control Release ; 288: 161-172, 2018 10 28.
Article em En | MEDLINE | ID: mdl-30217739
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sistemas de Liberação de Medicamentos / Fator A de Crescimento do Endotélio Vascular / Proteínas Inativadoras de Ribossomos Tipo 1 / Neoplasias / Antineoplásicos Fitogênicos Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sistemas de Liberação de Medicamentos / Fator A de Crescimento do Endotélio Vascular / Proteínas Inativadoras de Ribossomos Tipo 1 / Neoplasias / Antineoplásicos Fitogênicos Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2018 Tipo de documento: Article